MA
Mayne Pharma Group Limited
MAYNF · OTC
$2.15 -6.52% (-$0.15)
1M -6.52%
Market Cap $262.6M
P/E Ratio 10.74x
Div. Yield -
ROE 6.27%
Bulios Fair Price
$1.59
26.0% downside
Current Price
$2.15
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MAYNF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
89 /100
Cheap EV/EBITDA 7.61x
P/S 0.69x
P/B 0.67x
Growth
78 /100
Growing Book val. growth 14.94%
Rev. growth 27.79%
FCF growth N/A
Profitability
37 /100
Moderate Net margin 6.38%
Op. margin 8.94%
FCF margin 3.30%
Quality
18 /100
Poor ROE 6.27%
ROA 2.69%
Asset turnover 0.42x
Debt
74 /100
Low Current ratio 1.31x
Int. coverage -6.46x
Net debt/EBITDA -1.33x
Stability
39 /100
Moderate Rev. volatility 64.86%
EPS volatility 42.37%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MAYNF
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Aaron Gray
Employees
450
Headquarters
Salisbury South
Upcoming events
24 FEB
Earnings
Upcoming earnings report